37.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$38.61
Aprire:
$38.05
Volume 24 ore:
3.09M
Relative Volume:
0.90
Capitalizzazione di mercato:
$3.70B
Reddito:
$2.23B
Utile/perdita netta:
$-248.39M
Rapporto P/E:
-13.98
EPS:
-2.69
Flusso di cassa netto:
$-697.55M
1 W Prestazione:
-0.79%
1M Prestazione:
-38.21%
6M Prestazione:
-71.80%
1 anno Prestazione:
-69.79%
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SRPT
Sarepta Therapeutics Inc
|
37.60 | 3.72B | 2.23B | -248.39M | -697.55M | -2.69 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
2025-04-11 | Iniziato | Wells Fargo | Overweight |
2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-11 | Iniziato | Deutsche Bank | Hold |
2024-11-27 | Reiterato | Needham | Buy |
2024-11-25 | Iniziato | H.C. Wainwright | Sell |
2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2024-10-21 | Iniziato | Jefferies | Buy |
2024-10-10 | Ripresa | Raymond James | Outperform |
2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
2024-05-31 | Iniziato | Piper Sandler | Overweight |
2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
2023-12-13 | Ripresa | Citigroup | Buy |
2023-12-12 | Iniziato | Deutsche Bank | Buy |
2023-11-21 | Iniziato | Wedbush | Outperform |
2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
2023-04-26 | Iniziato | SMBC Nikko | Outperform |
2023-04-04 | Iniziato | Citigroup | Buy |
2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2022-12-22 | Reiterato | BTIG Research | Buy |
2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
2022-01-05 | Reiterato | Needham | Buy |
2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
2021-06-15 | Iniziato | BTIG Research | Buy |
2021-04-26 | Ripresa | Credit Suisse | Neutral |
2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
2021-01-11 | Downgrade | UBS | Buy → Neutral |
2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
2020-11-11 | Iniziato | Berenberg | Hold |
2020-10-28 | Iniziato | UBS | Buy |
2020-08-25 | Iniziato | Raymond James | Outperform |
2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
2020-03-31 | Iniziato | Mizuho | Buy |
2019-11-01 | Iniziato | Guggenheim | Buy |
2019-08-21 | Reiterato | Needham | Buy |
2019-07-09 | Reiterato | Morgan Stanley | Overweight |
2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2019-03-11 | Reiterato | Credit Suisse | Outperform |
2018-10-12 | Iniziato | Bernstein | Outperform |
2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
2018-09-14 | Ripresa | BofA/Merrill | Buy |
2018-09-06 | Iniziato | Credit Suisse | Outperform |
2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2018-06-21 | Reiterato | Robert W. Baird | Outperform |
2018-06-20 | Reiterato | Needham | Buy |
2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg.com
July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq
We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st
Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus
Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey
FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters
Was Jim Cramer Right About These 11 Stocks? - Insider Monkey
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com
Will Moderna's Rally Continue? - Forbes
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent
FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive
SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus
Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus
Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance
Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus
Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch
Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha
Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus
Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus
Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus
Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance
Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance
Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus
Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus
Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News
Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus
Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus
Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com
Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus
Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus
Sarepta Seeks to Strengthen Elevidys’ Case With Data in Older Kids - BioSpace
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - itemonline.com
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire
Nucleic Acid Therapeutics Market Trends, Size & Growth Forecast - openPR.com
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore - Yahoo Finance
Sarepta at BofA Conference: Navigating Challenges and Growth - Investing.com
Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates - Yahoo Finance
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore - MarketBeat
Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns - TipRanks
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):